196 related articles for article (PubMed ID: 23712757)
1. Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.
Brennan BJ; Moreira SA; Morcos PN; Navarro MT; Asthappan J; Goelzer P; Weigl P; Smith PF
Clin Pharmacokinet; 2013 Sep; 52(9):805-13. PubMed ID: 23712757
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir.
Brennan BJ; Poirier A; Moreira S; Morcos PN; Goelzer P; Portmann R; Asthappan J; Funk C; Smith PF
Clin Pharmacokinet; 2015 May; 54(5):537-49. PubMed ID: 25488594
[TBL] [Abstract][Full Text] [Related]
3. Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.
Reddy MB; Chen Y; Haznedar JO; Fretland J; Blotner S; Smith P; Tran JQ
Clin Pharmacokinet; 2012 Jul; 51(7):457-65. PubMed ID: 22624502
[TBL] [Abstract][Full Text] [Related]
4. A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.
Morcos PN; Chang L; Kulkarni R; Giraudon M; Shulman N; Brennan BJ; Smith PF; Tran JQ
Eur J Clin Pharmacol; 2013 Nov; 69(11):1939-49. PubMed ID: 23872824
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
6. Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjects.
Morcos PN; Chang L; Navarro M; Chung D; Smith PF; Brennan BJ; Tran JQ
Int J Clin Pharmacol Ther; 2014 Feb; 52(2):103-11. PubMed ID: 24290411
[TBL] [Abstract][Full Text] [Related]
7. Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy.
Moreira SA; Morcos PN; Navarro MT; Bech N; Smith PF; Brennan BJ
Pharmacotherapy; 2014 Mar; 34(3):220-6. PubMed ID: 23946152
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors.
Khurana V; Minocha M; Pal D; Mitra AK
Drug Metabol Drug Interact; 2014; 29(4):249-59. PubMed ID: 24807167
[TBL] [Abstract][Full Text] [Related]
10. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
Gane EJ; Rouzier R; Stedman C; Wiercinska-Drapalo A; Horban A; Chang L; Zhang Y; Sampeur P; Nájera I; Smith P; Shulman NS; Tran JQ
J Hepatol; 2011 Nov; 55(5):972-9. PubMed ID: 21354234
[TBL] [Abstract][Full Text] [Related]
11. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
[TBL] [Abstract][Full Text] [Related]
12. Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice.
Loos NHC; Ferreira Martins ML; Rijmers J; de Jong D; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
Mol Pharm; 2024 Apr; 21(4):1952-1964. PubMed ID: 38423793
[TBL] [Abstract][Full Text] [Related]
13. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
Treiber A; Schneiter R; Häusler S; Stieger B
Drug Metab Dispos; 2007 Aug; 35(8):1400-7. PubMed ID: 17496208
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Forestier N; Larrey D; Guyader D; Marcellin P; Rouzier R; Patat A; Smith P; Bradford W; Porter S; Blatt L; Seiwert SD; Zeuzem S
J Hepatol; 2011 Jun; 54(6):1130-6. PubMed ID: 21145848
[TBL] [Abstract][Full Text] [Related]
15. Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers.
Morcos PN; Moreira SA; Navarro MT; Bech N; Quatkemeyer A; Smith PF; Brennan BJ
J Pharm Pharmacol; 2014 Jan; 66(1):23-31. PubMed ID: 24117531
[TBL] [Abstract][Full Text] [Related]
16. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.
Annaert P; Ye ZW; Stieger B; Augustijns P
Xenobiotica; 2010 Mar; 40(3):163-76. PubMed ID: 20102298
[TBL] [Abstract][Full Text] [Related]
17. Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers.
Yu CY; Campbell SE; Sponseller CA; Small DS; Medlock MM; Morgan RE
Clin Drug Investig; 2014 Jul; 34(7):475-82. PubMed ID: 24825411
[TBL] [Abstract][Full Text] [Related]
18. Isolation of modulators of the liver-specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae).
Roth M; Araya JJ; Timmermann BN; Hagenbuch B
J Pharmacol Exp Ther; 2011 Nov; 339(2):624-32. PubMed ID: 21846839
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
